1. In Vivo
  2. >>Growth

Olympus Targets A Bigger Medical Future

 
• By Ashley Yeo

A medical company that has some other businesses – that is the shorthand description that Olympus Corp. of the Americas president and CEO Nacho Abia ascribes to a group that has emerged from difficult times with a new strategy, new structure and new determination. Targeted deals and M&A remain as important as ever to the group as it embarks, somewhat reinvented, on a new five-year plan.

IV1608_Target-Arrow_1200x675

The past is the past, and we have to learn from it, says Olympus Corp. of the Americas (Center Valley, PA) president and CEO Nacho Abia. He is talking to In Vivo during the ninth annual Global Medtech Compliance Conference (GMTCC), in Dublin, Ireland. His attendance on a panel discussing broad themes revolving around the importance of compliance speaks volumes for a company that has suffered all the negative attention that a financial scandal brings with it.

Abia is in fact keen to shine the spotlight onto a group where he has had responsibilities at the senior...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy